← Back to front page
United States · Platforms & data · Benzinga

FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder

Published by Benzinga · United States 39 min ago
FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder
Benzinga

Detailed summary

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced on Monday that the U.S. Food and Drug Administration (FDA) approved IGALMI (dexmedetomidine) sublingual film for at-home…

Read the full article on Benzinga Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.benzinga.com)

Also worth reading